Dopamine antagonists for treatment resistance in autism spectrum disorders: review and focus on BDNF stimulators loxapine and amitriptyline

References

• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington (VA): American Psychiatric Association; 2013.
   Google Scholar
• Aman MG, Lam KSL, Van Bourgondien ME. Medication patterns in patients with autism: temporal, regional and demographic influences. J Child Adolesc Psychopharmacol. 2005;15:116–126.
   PubMed Web of Science ®Google Scholar
• Murray ML, Hsia Y, Glaser K, et al. Pharmacologic treatment prescribed to people with autism spectrum disorders (ASD) in primary health care. Psychopharmacology. 2014;23(6):1011–1021.
   Google Scholar
• Park SY, Cervesi C, Galling B, et al. Antispychotic use trends in youth with autism spectrum disorder and/or intellectual disability: a met-analysis. J Am Acad Child Adolesc Psychiatry. 2016;55(6):456–458.
   PubMed Web of Science ®Google Scholar
• Bhatti I, Thome A, Smith PO, et al. A retrospective study of amitriptyline in youth with autism spectrum disorders. J Autism Dev Disord. 2013;43(5):1017–1027.
   PubMed Web of Science ®Google Scholar
• Hellings JA. Much improved outcome with gabapentin – divalproex combination in adults with bipolar disorders and developmental disabilities. J Clin Psychopharmacol. 2006;26(3):344–346.
   PubMed Web of Science ®Google Scholar
• Freedman R. 2015 in review: revisiting early drug discovery. Editorial. Am J Psychiatry. 2015;172(120):1179.
   PubMedGoogle Scholar
• Hellings JA, Jadhav M, Jain S, et al. Low dose loxapine: neuromotor side effects and tolerability in autism spectrum disorders. J Child Adolesc Psychopharmacol. 2015a;25(8):618–624.
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, et al.; For the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209–1223.
   PubMed Web of Science ®Google Scholar
• Meltzer HY. Clozapine: balancing safety with superior antipsychotic efficacy. Clin Schizophr Relat Psychoses. 2012;6(3):134–144.
   PubMedGoogle Scholar
• Campbell M, Anderson LT, Meier M, et al. A comparison of haloperidol and behavior therapy and their interaction in autistic children. J Am Acad Child Adolesc Psychiatry. 1978;17(4):640–655.
   Web of Science ®Google Scholar
• Cohen IL, Campbell M, Posner D, et al. Behavioral effects of haloperidol in young autistic children: am objective analysis using a within-subjects reversal design. J Am Acad Child Adolesc Psychiatry. 1980;19:655–677.
   Web of Science ®Google Scholar
• Perry R, Campbell M, Adams P, et al. Long-term efficacy of haloperidol in autistic children: continuous versus discontinuous administration. J Am Acad Child Adolesc Psychiatry. 1989;28(1):87–92.
   PubMed Web of Science ®Google Scholar
• Yassa R, Iskandar H, Ally J. The prevalence of tardive dyskinesia in fluphenazine-treated patients. J Clin Psychopharmacol. 1988;8(4 Suppl):17S−20S.
   Google Scholar
• Breuning SE, Ferguson DG, Davidson NA, et al. Effects of thioridazine on the intellectual performance of mentally retarded drug responders and nonresponders. Arch Gen Psychiatry. 1983;40(3):309–313.
   PubMedGoogle Scholar
• Aman MG, Singh NN. A critical appraisal of recent drug research in mental retardation: the coldwater studies. J Ment Defic Res. 1986;30:203–216.
   PubMedGoogle Scholar
• Campbell M, Geller B, Cohen IL. Current status of drug research and treatment with autistic children. J Pediatr Psychol. 1977;2:153–161.
   Google Scholar
• Koga M. Clinical factors related to gains in body mass index (BMI) among patients under long-term antipsychotic treatment [Article in Japanese]. Seishin Shinkeiqaku Zassi. 2003;105(4):473–488.
   PubMedGoogle Scholar
• Seeman M. Secondary effects of antipsychotics: women at greater risk than men. Schizophrenia Bull. 2009;35(5):937–948.
   PubMed Web of Science ®Google Scholar
• Bagnell AM, Fenton M, Lewis R, et al. Molindone for schizophrenia and severe mental illness. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD002083.
   Google Scholar
• Hellings JA, Zarcone JR, Crandall K, et al. Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism. J Child Adolesc Psychopharmacol. 2001 Fall;11(3):229–238.
   PubMed Web of Science ®Google Scholar
• Findling RL, Kusumakar V, Daneman D, et al. Prolactin levels during long term risperidone treatment in children and adolescents. J Clin Psychiatry. 2003;64(11):1362–1369.
   PubMed Web of Science ®Google Scholar
• Hellings JA, Cardona A, Schroeder SR. Long-term safety and adverse events of risperidone in children, adolescents and adults with pervasive developmental disorders. J Mental Health Research Intell Disabil. 2010;3:132–144.
   Web of Science ®Google Scholar
• Correll CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009;302(16):1765–1773.
   PubMed Web of Science ®Google Scholar
• Hellings JA, Boehm D, Yeh H, et al. Long-term clinical aripiprazole efficacy and weight changes in youth with developmental disabilities including autism spectrum disorders. J. Ment Health Res Intell Disabil. 2011;4:1–14.
   Web of Science ®Google Scholar
• Marcus RN, Owen R, Manos G, et al. Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: a 52-week, open-label, multicenter study. J Clin Psychiatry. 2011;72(9):1270–1276.
   PubMed Web of Science ®Google Scholar
• Roerig IL, Steffen KI, Mitchell IE. Atypical antipsychotic-induced weight gain: insights into mechanisms of action. CNS Drugs. 2011;25(12):1035.
   PubMed Web of Science ®Google Scholar
• Correll CU, Carlson HE. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry. 2006;45(7):771–791.
   PubMed Web of Science ®Google Scholar
• Beherec L, Lambrey S, Quilici G, et al. Retrospective review of clozapine in the treatment of patients with autism spectrum disorders and severe disruptive behaviors. J Clin Psychopharmacol. 2011;31(3):341–344.
   PubMed Web of Science ®Google Scholar
• Gobbi G, Pulvirente L. Long-term treatment with clozapine in an adult with autistic disorder accompanied by aggressive behavior. J Psychiatry Neurosci. 2001;26(4):340–341.
   PubMed Web of Science ®Google Scholar
• Stahl SM. Essential psychopharmacology of antipsychotics and mood stabilizers. Cambridge, UK: Cambridge University Press; 2002.
   Google Scholar
• Kapur S, Zipursky R, Remington G, et al. PET evidence that loxapine is an equipotent blocker of 5-HT2 and D2 receptors: implications for the therapeutics of schizophrenia. Am J Psychiatry. 1997;154:1525–1529.
   PubMed Web of Science ®Google Scholar
• Li Z, Ichikawa J, Meltzer H. A comparison of the effects of loxapine with ziprasidone and thioridazine on the release of dopamine and acetylcholine in the prefrontal cortex and nucleus accumbens. Psychopharmacology. 2003;167:315–323.
   PubMed Web of Science ®Google Scholar
• Popovic D, Nuss P, Vieta E. Revisiting loxapine: a systematic review. Ann Gen Psychiatry. 2015;14:15. Published online 2015 Apr 1.
   PubMed Web of Science ®Google Scholar
• Hellings JA, Reed G, Cain SE, et al. Loxapine add-on for adolescents and adults with autism spectrum disorders, aggression and irritability. J Child Adolesc Psychopharmacol. 2015;25(2):150–159.
   PubMed Web of Science ®Google Scholar
• Jain S, Andridge R, Hellings JA. Loxapine substitution for reversal of antipsychotic-induced metabolic disturbances: a chart review. J Autism Dev Disord. 2016;46:1344–1353.
   PubMed Web of Science ®Google Scholar
• Noble EE, Billington CJ, Kotz CM, et al. The lighter side of BDNF. Am J Physiol Regul Integr Comp Physiol. 2011;300(5):R1053–R1069.
   PubMed Web of Science ®Google Scholar
• Brennand KJ, Simone A, Jou J, et al. Modeling schizophrenia using human pluripotent stem cells. Nature. 2011;473:221–225.
   PubMed Web of Science ®Google Scholar
• Dorph-Peterson K-A, Pierri JN, Perel JM, et al. The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys. Neuropsychopharmacology. 2005;30:1649–1661.
   PubMed Web of Science ®Google Scholar
• Singh AN, Barla C, Singh S, et al. A neurochemical basis for the antipsychotic activity of loxapine: interactions with dopamine D1, D2, D4, and serotonin 5-HT2 receptor subtypes. J Psychiatry Neurosci. 1996;21(1):29–35.
   PubMed Web of Science ®Google Scholar
• Citrome L. Addressing the need for rapid treatment of agitation in schizophrenia and bipolar disorder: focus on inhaled loxapine as an alternative to injectable agents. Ther Clin Risk Manag. 2013;9:235–245.
   PubMed Web of Science ®Google Scholar
• Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry. 2008;21(2):151–156.
   PubMed Web of Science ®Google Scholar
• Guy W. Assessment manual for psychopharmacology. Washington (DC): US Government Printing Office; 1976.
   Google Scholar
• Aman MG, Burrow WH, Wolford PL. The aberrant behavior checklist-community: factor validity and effect of subject variables for adults in group homes. Am J Ment Retard. 1995;100:283–292.
   PubMedGoogle Scholar
• Schalock RL, Brown I, Brown B, et al. Conceptualization, measurement, and application of quality of life for persons with intellectual disabilities: report of an international panel of experts. Ment Retardationn. 2002;40(6):457–470.
   PubMedGoogle Scholar
• Lam KS, Aman MG. The repetitive behavior scale-revised: independent validation in individuals with autism spectrum disorders. J Autism Dev Disord. 2007;37:855–866.
   PubMed Web of Science ®Google Scholar
• Horvath K, Perman JA. Autistic disorder and gastrointestinal disease. Curr Opin Pediatr. 2002;14(5):583–587.
   PubMed Web of Science ®Google Scholar
• Pollard AJ, Prendergast M. Depressive pseudodementia in a child with autism. Dev Med Child Neurol. 2004;46:485–489.
   PubMed Web of Science ®Google Scholar
• Chadwick W, Mitchell N, Caroll J, et al. Amitriptyline-mediated cognitive enhancement in aged 3X tg Alzheimer’s disease mice is associated with neurogenesis and neurotrophic activity. PLos One. 2011;6:e21660.
   PubMedGoogle Scholar
• Zheng Z, Zhang L, Zhu T, et al. Peripheral brain-derived neurotrophic factor in autism spectrum disorder: a systematic review and meta-analysis. Sci Rep. 2016;6. article number: 31241. DOI:10.1038/srep31241
   Web of Science ®Google Scholar
• King BH, Hollander E, Sikich L, et al. Lack of efficacy of citalopram in children with autism spectrum disorder and high levels of repetitive behaviors. JAMA Psychiatry. 2009;66(6):583–590.
   Google Scholar
• Williams K, Wheeler DM, Silove N, et al. Selective serotonin reuptake inhibitors for autism spectrum disorders. Cochrane Database Syst Rev. 2010;4(8):CD004677.
   Google Scholar